FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Real-time Bid/Ask 06:58:22 24/06/2024 pm IST | ||
| 6.85 EUR / 6.86 EUR | +0.51% |
|
| Current month | -6.06% | ||
| 1 month | -3.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 6.87 | +0.73% |
| 21/24/21 | 6.82 | -3.12% |
| 20/24/20 | 7.04 | -1.26% |
| 19/24/19 | 7.13 | +3.18% |
| 18/24/18 | 6.91 | +0.14% |
Delayed Quote Börse Stuttgart
Last update June 24, 2024 at 02:49 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MG0CVJ |
| ISIN | DE000MG0CVJ0 |
| Date issued | 18/03/2024 |
| Strike | 18,708 p |
| Maturity | Unlimited |
| Parity | 10.77 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.46 € |
|---|---|
| Lowest since issue | 6.7 € |
| Spread | 0.01 € |
| Spread % | 0.15% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.5
USD
Average target price
174.4
USD
Spread / Average Target
+10.77%
- Stock Market
- Certificates
- Certificat
